ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY

ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY

To evaluate the effects of betrixaban on individual heart rate-corrected QT duration (QTcl), 96 healthy adults were randomly assigned to single-dose betrixaban 80 mg and 140 mg (therapeutic and supratherapeutic doses, respectively), placebo, and moxifloxacin 400 mg (positive control) in a 4-period c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2013-03, Vol.61 (10), p.E271-E271
Hauptverfasser: Sinha, Uma, Morganroth, Joel, Gretler, Daniel D, Hollenbach, Stanley J, Lambing, Joseph L
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cardiovascular
Confidence intervals
Drug therapy
Internal Medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate the effects of betrixaban on individual heart rate-corrected QT duration (QTcl), 96 healthy adults were randomly assigned to single-dose betrixaban 80 mg and 140 mg (therapeutic and supratherapeutic doses, respectively), placebo, and moxifloxacin 400 mg (positive control) in a 4-period crossover study.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(13)60271-5